Effects of Green Tea Extracts on Gastric Mucosal Protection

Pusan National University Yangsan Hospital24 enrolled

Overview

The investigators conduct a randomized, double-blind, placebo-controlled pilot study to investigate the effects of a combined extract of green tea seed (saponins) and green tea leaves (epigallocatechin-3-gallate) on gastric mucosal protection in adults with functional dyspepsia for 8 weeks.

A previous study has indicated that combined extract of green tea seed (saponins) and green tea leaves (epigallocatechin-3-gallate) may improve gastric mucosal status in rat with alcohol-induced gastritis.Therefore, the investigators conduct a randomized, double-blind, placebo-controlled pilot study to investigate the effects of a combined extract of green tea seed (saponins) and green tea leaves (epigallocatechin-3-gallate) on gastric mucosal protection in adults with functional dyspepsia for 8 weeks; the safety of the compound are also evaluated. The Investigators examine C-reactive protein, IFN-γ, TNF-α, gastrin, malondialdehyde, 8-hydroxy-2' -deoxyguanosine, and questionnaires (Gastrointestinal Symptom Rating Scale, Nepean dyspepsia index-Korean version, Nepean dyspepsia index-Korean version QOL questionnaire, Gastrointestinal symptom scale) at baseline and after 8 weeks of intervention. Twenty four adults were administered either 320 mg of combined extracts of green tea seed (saponins) and green tea leaves (epigallocatechin-3-gallate) or a placebo each day for 8 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Functional Dyspepsia

Interventions

Green tea combined extracts groupDIETARY_SUPPLEMENT

Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks

Placebo groupDIETARY_SUPPLEMENT

Placebo 320 mg/day during 8 weeks

Eligibility

Sex: ALLMin age: 19 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * The Rome IV criteria define dyspepsia as any combination of 4 symptoms: postprandial fullness, early satiety, epigastric pain, and epigastric burning that are severe enough to interfere with the usual activities and occur at least 3 days per week over the last 3 months Exclusion Criteria: * Patients complaining of severe gastrointestinal symptoms requiring immediate medication * Those with a history of gastric acid hypersecretion such as Zollinger-Ellison Syndrome * Those who received Helicobacter pylori eradication therapy within 4 weeks * Those who have taken nonsteroidal anti-inflammatory drugs, steroid drugs or antibiotics, aspirin or antithrombotic drugs, or gastric acid suppressants within 4 weeks * Those who have a history of upper gastrointestinal tract surgery, stenosis, bleeding, esophageal dilatation, gastric mucosal resection, etc. within the past 1 year * Patients with gastric ulcer (active or healing), duodenal ulcer (active or healing), reflux esophagitis (LA B or higher), or malignant tumors from gastroscopy performed within the last 6 months * Abnormal liver or renal function (more than twice the normal upper limit of the research institute) * Uncontrolled diabetes mellitus (\>160 mg/dL of fasting blood sugar) * History of fracture during the previous year * Uncontrolled hypertension (\>160/100 mmHg) * Uncontrolled thyroid diseases. * History of serious cerebro-cardiovascular diseases or cancer such as angina or myocardial infarction within 6 months * History of any central bone fracture within 1 year * History of medication for psychiatric diseases such as severe depression, schizophrenia, drug intoxication. * Alcohol abuser * Allergic reaction to Ishige Okamurae * Those who participated in other drug clinical trials within 1 month from the screening date. * Severe gastrointestinal symptoms such as heartburn and indigestion * Those who are pregnant, lactating, or plan to become pregnant during the clinical trial * Those who are judged to be unsuitable by the PI for other reasons

Locations (1)

Pusan National University Yangsan Hospital

Yangsan, Gyeungsangnam-do, South Korea

Outcomes

Primary Outcomes

Gastrointestinal Symptom Rating Scale (score)

Gastrointestinal Symptom Rating Scale - questionnaire evaluated at baseline and after 8 weeks. It ranges from the minimum of 0 to the maximum of 75. A higher score indicates a worse outcome.

Time frame: 8 weeks

Secondary Outcomes

concentration of high-sensitivity C-reactive protein (mg/L)

high-sensitivity C-reactive protein (mg/L) measured at baseline and after 8 weeks

Time frame: 8 weeks

concentration of interferon-γ (pg/mL)

interferon-γ (pg/mL) measured at baseline and after 8 weeks

Time frame: 8 weeks

concentration of tumor necrosis factor-α (pg/mL)

interferon-γ (pg/mL) measured at baseline and after 8 weeks measured at baseline and after 8 weeks

Time frame: 8 weeks

concentration of gastrin (pg/mL)

gastrin (pg/mL) measured at baseline and after 8 weeks

Time frame: 8 weeks

concentration of malondialdehyde (mic·mol/L)

malondialdehyde (mic·mol/L) measured at baseline and after 8 weeks

Time frame: 8 weeks

concentration of 8-hydroxy-2' -deoxyguanosine (ng/100 mg of protein)

8-hydroxy-2' -deoxyguanosine (ng/100 mg of protein) measured at baseline and after 8 weeks

Time frame: 8 weeks

Nepean dyspepsia index-Korean version (score)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.